Health Canada approved Pfizer-BioNTech’s updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine ...

BioNTech's updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine formulations that protect against ...

Comirnaty targets the KP.2 subvariant of Omicron, replacing the previous version which targeted the XBB.1.5 subvariant ...

Pfizer-BioNTech's updated vaccine to protect against a recently circulating variant of COVID-19 is authorized, Health Canada said on Tuesday.

Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union ...

Pfizer and BioNTech said on Friday that a committee from the European Medicine Agency recommended marketing authorization for its Omicron adapted vaccine to prevent Covid-19, meaning the vaccine is ...

In comparison, at its current levels of around $195, AbbVie stock trades at 18x expected 2024 earnings of $10.88 per share. This compares with the 12x average P/E multiple for ABBV seen over the last ...

The company's best days as a top pandemic vaccine supplier might be over, but it still has enough potential to be compelling.

Novavax's traditional protein-based shot offers an alternative vaccine technology to those that are based on messenger RNA - Moderna's Spikevax and Comirnaty, which is jointly developed by Pfizer ...

During the pandemic, Pfizer gave the world the first and most widely used vaccine, Comirnaty, and the oral antiviral pill, Paxlovid. Though in 2021/2022, no company was as strongly placed as ...

Given its better valuation, we believe that Pfizer stock (NYSE: PFE) is currently a better pick than its industry peer – AbbVie stock (NYSE:ABBV). PFE stock trades at a much lower multiple of 11x ...